Literature DB >> 30337373

Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming.

Marina Koutsioumpa1, Maria Hatziapostolou2,3, Christos Polytarchou4, Ezequiel J Tolosa5, Luciana L Almada5, Swapna Mahurkar-Joshi1, Jennifer Williams6, Ana Belen Tirado-Rodriguez7, Sara Huerta-Yepez7, Dimitrios Karavias8, Helen Kourea8, George A Poultsides9, Kevin Struhl10, David W Dawson11, Timothy R Donahue6, Martín E Fernández-Zapico5, Dimitrios Iliopoulos1.   

Abstract

OBJECTIVE: Despite advances in the identification of epigenetic alterations in pancreatic cancer, their biological roles in the pathobiology of this dismal neoplasm remain elusive. Here, we aimed to characterise the functional significance of histone lysine methyltransferases (KMTs) and demethylases (KDMs) in pancreatic tumourigenesis.
DESIGN: DNA methylation sequencing and gene expression microarrays were employed to investigate CpG methylation and expression patterns of KMTs and KDMs in pancreatic cancer tissues versus normal tissues. Gene expression was assessed in five cohorts of patients by reverse transcription quantitative-PCR. Molecular analysis and functional assays were conducted in genetically modified cell lines. Cellular metabolic rates were measured using an XF24-3 Analyzer, while quantitative evaluation of lipids was performed by liquid chromatography-mass spectrometry (LC-MS) analysis. Subcutaneous xenograft mouse models were used to evaluate pancreatic tumour growth in vivo.
RESULTS: We define a new antitumorous function of the histone lysine (K)-specific methyltransferase 2D (KMT2D) in pancreatic cancer. KMT2D is transcriptionally repressed in human pancreatic tumours through DNA methylation. Clinically, lower levels of this methyltransferase associate with poor prognosis and significant weight alterations. RNAi-based genetic inactivation of KMT2D promotes tumour growth and results in loss of H3K4me3 mark. In addition, KMT2D inhibition increases aerobic glycolysis and alters the lipidomic profiles of pancreatic cancer cells. Further analysis of this phenomenon identified the glucose transporter SLC2A3 as a mediator of KMT2D-induced changes in cellular, metabolic and proliferative rates.
CONCLUSION: Together our findings define a new tumour suppressor function of KMT2D through the regulation of glucose/fatty acid metabolism in pancreatic cancer. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gene regulation; molecular oncology; pancreatic cancer

Mesh:

Substances:

Year:  2018        PMID: 30337373      PMCID: PMC6697184          DOI: 10.1136/gutjnl-2017-315690

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  41 in total

Review 1.  Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark.

Authors:  Alexander J Ruthenburg; C David Allis; Joanna Wysocka
Journal:  Mol Cell       Date:  2007-01-12       Impact factor: 17.970

2.  Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia.

Authors:  Davendra Segara; Andrew V Biankin; James G Kench; Catherine C Langusch; Amanda C Dawson; David A Skalicky; David C Gotley; Maxwell J Coleman; Robert L Sutherland; Susan M Henshall
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

3.  PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Authors:  Hongbing Zhang; Natalia Bajraszewski; Erxi Wu; Hongwei Wang; Annie P Moseman; Sandra L Dabora; James D Griffin; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

Review 4.  NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences.

Authors:  Weihai Ying
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

5.  Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity.

Authors:  Hiromichi Ito; Mark Duxbury; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Surgery       Date:  2004-09       Impact factor: 3.982

Review 6.  Tumor cell metabolism: cancer's Achilles' heel.

Authors:  Guido Kroemer; Jacques Pouyssegur
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

7.  Dependence of histone modifications and gene expression on DNA hypermethylation in cancer.

Authors:  Jill A Fahrner; Sayaka Eguchi; James G Herman; Stephen B Baylin
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

8.  Activating signal cointegrator-2 is an essential adaptor to recruit histone H3 lysine 4 methyltransferases MLL3 and MLL4 to the liver X receptors.

Authors:  Seunghee Lee; Jeongkyung Lee; Soo-Kyung Lee; Jae W Lee
Journal:  Mol Endocrinol       Date:  2008-03-27

9.  p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation.

Authors:  Keiko Kawauchi; Keigo Araki; Kei Tobiume; Nobuyuki Tanaka
Journal:  Nat Cell Biol       Date:  2008-04-06       Impact factor: 28.824

Review 10.  LKB1 kinase: master and commander of metabolism and polarity.

Authors:  James Spicer; Alan Ashworth
Journal:  Curr Biol       Date:  2004-05-25       Impact factor: 10.834

View more
  16 in total

Review 1.  Pathogenic and Therapeutic Role of H3K4 Family of Methylases and Demethylases in Cancers.

Authors:  Aman Kumar; Niti Kumari; Nayudu Nallabelli; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2019-04-03

2.  Epigenetic and metabolic interplay in cutaneous squamous cell carcinoma.

Authors:  Gina Pacella; Brian C Capell
Journal:  Exp Dermatol       Date:  2021-04-22       Impact factor: 3.960

3.  The Bidirectional Relationship Between Cancer Epigenetics and Metabolism.

Authors:  Luke T Izzo; Hayley C Affronti; Kathryn E Wellen
Journal:  Annu Rev Cancer Biol       Date:  2020-11-30

4.  Loss of Function of the Gene Encoding the Histone Methyltransferase KMT2D Leads to Deregulation of Mitochondrial Respiration.

Authors:  Consiglia Pacelli; Iolanda Adipietro; Natascia Malerba; Gabriella Maria Squeo; Claudia Piccoli; Angela Amoresano; Gabriella Pinto; Pietro Pucci; Ji-Eun Lee; Kai Ge; Nazzareno Capitanio; Giuseppe Merla
Journal:  Cells       Date:  2020-07-13       Impact factor: 6.600

5.  KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.

Authors:  Si-Si Li; Wei-Liang Jiang; Wen-Qin Xiao; Kai Li; Ye-Fei Zhang; Xing-Ya Guo; Yi-Qi Dai; Qiu-Yan Zhao; Ming-Jie Jiang; Zhan-Jun Lu; Rong Wan
Journal:  World J Gastrointest Oncol       Date:  2019-08-15

6.  LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit.

Authors:  Senlin Zhao; Bingjie Guan; Yushuai Mi; Debing Shi; Ping Wei; Yanzi Gu; Sanjun Cai; Ye Xu; Xinxiang Li; Dongwang Yan; Mingzhu Huang; Dawei Li
Journal:  Oncogene       Date:  2021-06-18       Impact factor: 9.867

Review 7.  Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors.

Authors:  Shilpa S Dhar; Min Gyu Lee
Journal:  Oncotarget       Date:  2021-06-22

8.  LINC00667 Promotes Progression of Esophageal Cancer Cells by Regulating miR-200b-3p/SLC2A3 Axis.

Authors:  Jindun Pan; Yunhong Zang
Journal:  Dig Dis Sci       Date:  2021-07-27       Impact factor: 3.487

Review 9.  The role of histone methylation in the development of digestive cancers: a potential direction for cancer management.

Authors:  Yuan Chen; Bo Ren; Jinshou Yang; Huanyu Wang; Gang Yang; Ruiyuan Xu; Lei You; Yupei Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-08-03

10.  Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death.

Authors:  Ligia I Bastea; Laeticia M A Hollant; Heike R Döppler; Elizabeth M Reid; Peter Storz
Journal:  Sci Rep       Date:  2019-11-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.